Intercept Pharmaceuticals, Inc.
ICPTDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Obeticholic acid (10 mg)
Compensated Cirrhosis
Obeticholic Acid (OCA)
Primary Biliary Cirrhosis
INT-747
Diabetes Mellitus, Type II
INT-787
Alcohol Associated Hepatitis
Obeticholic Acid
Primary Biliary Cirrhosis
Bezafibrate 100 mg
Primary Biliary Cholangitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Obeticholic acid (10 mg) | Phase 3 | Compensated Cirrhosis | - | - |
Obeticholic Acid (OCA) | Phase 3 | Primary Biliary Cirrhosis | - | - |
INT-747 | Phase 2 | Diabetes Mellitus, Type II | - | - |
INT-787 | Phase 2 | Alcohol Associated Hepatitis | - | - |
Obeticholic Acid | Phase 2 | Primary Biliary Cirrhosis | - | - |
Bezafibrate 100 mg | Phase 2 | Primary Biliary Cholangitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Intercept Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Intercept Pharmaceuticals, Inc.'s (ICPT) pipeline across Phase 3, Phase 2. Its lead program is Obeticholic acid (10 mg) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Intercept Pharmaceuticals, Inc.'s next FDA catalyst?→
Intercept Pharmaceuticals, Inc.'s (ICPT) next tracked catalyst is a Phase 2 expected September 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ICPT biotech catalysts?→
Add ICPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Intercept Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.